Prophylactic surgery in hereditary breast/ovarian cancer syndrome

ONCOLOGY

Volumn 17, Issue 7, 2003, Pages 932-941

  Levine, Douglas A ^a   Gemignani, Mary L ^b  

^a Department of Surgery

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347866110     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5- 26, 2003.
2. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1973-1999. National Cancer Institute, Bethesda, Md, 2002.
3. Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689, 1990.
4. Narod SA, Feunteun J, Lynch HT, et al: Familial breast-ovarian cancer locus on chromosome I7ql2-q23. Lancet 338:82-83, 1991.
5. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994.
6. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995.
7. Scully R, Livingston DM: In search of ther tumour-suppressor functions of BRCA1 and BRCA2. Nature 408:429-432, 2000.
8. Knudson AG: Two genetic hits (more or, less) to cancer. Nat Rev Cancer 1:157-162, 2001.
9. Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419, 2001.
10. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001.
11. Moslehi R, Chu W, Karlan B, et al: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259-1272, 2000.
12. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000.
13. Robson M, Levin D, Federici M, et al: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112- 2117, 1999.
14. Fodor FH, Weston A, Bleiweiss IJ, et al: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45-51, 1998.
15. Warner E, Foulkes W, Goodwin P, et al: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241-1247, 1999.
16. Newman B, Mu H, Butler LM, et al: Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915-921, 1998.
17. Foulkes WD, Wong N, Brunet JS, et al: Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465-2469, 1997.
18. Hartge P, Struewing JP, Wacholder S, et al: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963-970, 1999.
19. Takahashi H, Behbakht K, McGovern PE, et al: Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55:2998-3002, 1995.
20. Matsushima M, Kobayashi K, Emi M, et al: Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: Four germ- line mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953-1956, 1995.
21. Takahashi H, Chiu HC, Bandera CA, et al: Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56:2738-2741, 1996.
22. Stratton JF, Gayther SA, Russell P, et al: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336:1125-1130, 1997.
23. Yamashita Y, Sagawa T, Fujimoto T, et al: BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening. Breast Cancer Res Treat 58:11-17, 1999.
24. Tonin PM, Mes-Masson AM, Narod SA, et al: Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 55:318-324, 1999.
25. Yazici H, Glendon G, Bumie SJ, et al: BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: A high incidence of mutations in non-familial cases. Hum Mutat 20:28-34, 2002.
26. Modan B, Hartge P, Hirsh-Yechezkel G, et al: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutatioa N Engl J Med 345:235-240, 2001.
27. Schorge JO, Muto MG, Lee SJ, et al: BRCAI-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 60:1361-1364, 2000.
28. Menczer J, Chetrit A, Barda G, et al: Frequency of B RCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 88:58-61, 2003.
29. Aziz S, Kuperstein G, Rosen B, et al: A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80:341-345, 2001.
30. Liu FS, Ho ESC, Shih RT, et al: Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol 66:449-453, 1997.
31. Goshen R, Chu W, Elit L, et al: Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 79:477-481, 2000.
32. Levine DA, Lin O, Barakat RR, et al: Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 80:395-398, 2001.
33. Satagopan JM, Offit K, Foulkes W, et al: The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 10:467-473, 2001.
34. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N Engl J Med 336:1401-1408, 1997.
35. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002.
36. Hopper JL, Southey MC, Dite GS, et al: Population-based estimate of the average age- specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8:741-747, 1999.
37. Moller P, Borg A, Evans DG, et al: Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy, int J Cancer 101:555-559, 2002.
38. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998.
39. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCAl-muta- tion carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271, 1995.
40. Satagopan JM, Boyd J, Kauff ND, et al: Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8:3776-3781, 2002.
41. Levine DA, Federici MG, Reuter VE, et al: Cell proliferation and apoptosis in BRCA- associated hereditary ovarian cancer. Gynecol Oncol 85:431-434, 2002.
42. Phelan CM, Rebbeck TR, Weber BL, et al: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12:309-311, 1996.
43. Levy-Lahad E, Lahad A, Eisenberg S, et al: A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U SA 98:3232-3236, 2001.
44. Rebbeck TR, Kantoff PW, Krithivas K, et al: Modification of BRCAl-associated breast cancer risk by the polymorphic androgen-re- ceptor CAG repeat. Am J Hum Genet 64:1371-1377, 1999.
45. Rebbeck TR, Wang Y, Kantoff PW, et al: Modification of BRCA1- and BRCA2-asso- ciated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61:5420-5424, 2001.
46. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999.
47. Thompson D, Easton DF: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002.
48. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999.
49. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001.
50. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001.
51. McDonnell SK, Schaid DJ, Myers JL, et al: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938-3943, 2001.
52. Peralta EA, Ellenhorn JD, Wagman LD, et al: Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439-445, 2000.
53. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002.
54. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002.
55. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999.
56. Lu KH, Garber JE, Cramer DW, et al: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728-2732, 2000.
57. Colgan TJ, Murphy J, Cole DE, et al: Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283-1289, 2001.
58. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002.
59. Colgan TJ, Boerner SL, Murphy J, et al: Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy. Gynecol Oncol 85:397-403, 2002.
60. Wheeler JE: Diseases of the fallopian tube, in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, pp 529-532. New York, Springer-Verlag, 1994.
61. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994.
62. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 90:1371-1388, 1998.
63. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al: Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy. J Clin Oncol 20:2092-2100, 2002.
64. Schrag D, Kuntz KM, Garber JE, et al: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283:617-624, 2000.
65. Kuerer HM, Hwang ES, Anthony JP, et al: Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol 7:325-332, 2000.
66. Kauff ND, Scheuer L, Robson ME, et al: Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 3:422-425, 2001.
67. Meiser B, Butow P, Friedlander M, et al: Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 18:2250-2257, 2000.
68. Metcalfe KA, Narod SA: Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 94:1564-1569, 2002.
69. Montgomery IX, Tran KN, Heelan MC, et al: Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6:546-552, 1999.
70. Payne DK, Biggs C, Tran KN, et al: Women's regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 7:150-154, 2000.
71. Frost MH, Schaid DJ, Sellers TA, et al: Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324, 2000.
72. Fry A, Rush R, Busby-Earle C, et al: Deciding about prophylactic oophorectomy: What is important to women at increased risk of ovarian cancer? Prev Med 33:578-585, 2001.
73. Meiser B, Butow P, Barratt A, et al: Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75:122-129, 1999.
74. Wagner TM, Moslinger R, Langbauer G, et al: Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 82:1249-1253, 2000.
75. Tiller K, Meiser B, Butow P, et al: Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: A prospective study. Gynecol Oncol 86:212-219, 2002.
76. Aamio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218, 1999.
77. Dunlop MG, Farrington SM, Carothers AD, et al: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105-110, 1997.
78. Vasen HF, Wijnen JT, Menko FH, et al: Cancer risk in families with hereditary non- polyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020-1027, 1996.
79. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339:424-428, 1998.